Scoreboard / NTRA
Natera, Inc. NTRA
Week of September 10 to September 18, 2026 · Updated September 18, 2026
Setup Snapshot
The Setup in One Card
How NTRA scored, how it moved against the market, and the catalyst behind the move. A high score means the stock deserves research time, not that it is a buy.
Friday Five Score
Weekly Rank
05 of 5
Sector Trend
Leadingup 1.6 percent
Actionability
Extended
Catalyst
Clinical DataLargest molecular residual disease dataset ever presented in lung cancer showed strong prognostic value for Signatera.
Returns are measured from the Thursday, September 10 close to the Friday, September 18 close. Benchmarks: S&P 500 +0.8% and Nasdaq Composite +1.7% for the week. Benchmark figures are official index closes; sector figures use SPDR sector ETF closes because the official S&P sector index closes for this window were not yet published at press time.
Why It Moved
The Story Behind the Move
Catalyst
At the World Conference on Lung Cancer, Natera presented data on 1,129 patients with resected stage 1 to 3 non small cell lung cancer, the largest molecular residual disease dataset shown in the disease. Patients who tested positive after surgery carried roughly five times the risk of recurrence or death. The company published the release on September 18 and the stock rose 13.26 percent on the week, closing at a record 369.39 dollars.
Why It Mattered
Evidence at this scale is what moves a test from useful to standard of care, and it arrives while revenue is already growing 37.8 percent.
Risk Note
The company is not profitable, reporting a net loss of 192.35 million dollars, and trades at roughly 19.6 times sales at 99.9 percent of its 52 week high. Prognostic data is not a reimbursement decision, and payers have to agree before the evidence becomes revenue.
Reader Takeaway
Natera now has the strongest dataset in its category and a price that already assumes payers will agree with it.
Continue the Research
Put NTRA Back in Context
The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.